SUPPLEMENT

Q1 2026 — Investor materials

Q1 2026PDF · 6 pages454 KB
March 23, 2026
2026 Q1 Economic Factors and J&J Announcements
Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well
as public commentary made by management during the quarter and recent earnings calls. Any additional information
included herein is provided as phasing considerations and should not be construed as guidance.
Phasing considerations:
As a reminder, please note the following:
• 	The impact of Stelara erosion in Q1 2025 was less pronounced.
• 	In 2026, we benefit from a 53 rd week in our financial calendar, which is worth approximately 100 basis points
to full year sales growth and neutral to bottom line due to expenses for an additional week.
• 	We expect heavy investment in Q1 2026 compared to the rest of the year.
• 	For your convenience, as we progress through 2026, we have attached QTD and FY segment P&Ls for 2025.
Macro-economic factors:
• 	Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as
well as interest income on our cash position.
• 	Tariffs: In Q4 we noted a 2026 approximate impact of $500MM, exclusively related to our MedTech business,
based on tariff information known at the time. We are reviewing the impact of the Supreme Court’s decision
to deny the IEEPA tariff authority as well as the implementation of new tariffs through Section 122 at a flat
10%. We will provide further guidance as we have additional clarity on the financial impact of these decisions
and will continue to monitor tariffs and their potential impact to our business.
• 	Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to
experience, impacts to the Company's business resulting from the Russia-Ukraine war, conflict in the Middle
East as well as increasing tensions between the U.S. and China.

-- 1 of 6 --

• 	Foreign Exchange: We do not offer guidance or predictions on currency movements, but as highlighted by Joe
during the Q4 2025 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar as of mid-January
of 1.17 to give a sense of the potential impact on Full Year 2026 guidance. The Euro Spot Rate averaged 1.17 in
January, 1.18 in February, compared to a current spot rate of approximately 1.15 this past week. As a reminder,
our results are based on a basket of currencies, of which, not all align to the Euro.
Conference participation
J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for
the events below have been attached for your convenience.
• 	J.P. Morgan 44th Annual Healthcare Conference: Joaquin Duato – Chairman of the Board, Chief Executive
Officer, fireside chat with Christopher Schott - JPMorgan Chase & Co - Analyst
• 	TD Cowen 46th Annual Health Care Conference: Joseph Wolk – Chief Financial Officer, Executive Vice
President, fireside chat with Joshua Jennings - Cowen and Company LLC - Analyst
• 	Barclays 28th Annual Global Healthcare Conference: Hani Abouhalka – Company Group Chair, Surgery,
MedTech, fireside chat with Matt Miksic – Barclays Services Corp - Analyst

-- 2 of 6 --

Announcements
Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom,
and MedTech News & Events page.
• 	M&A: N/A
• 	Talc: please visit factsabouttalc.com for the latest company statements
• 	Enterprise: Next Generation Cell Therapy Manufacturing Facility; Agreement with U.S. Government to
Improve Access
• 	Innovative Medicine:
o 	CAPLYTA: Phase 3 data
o 	Erda-iDRS: Phase 1 Study
o 	ERLEADA: Head-to-Head analysis compares overall survival outcomes of ERLEADA
o 	ICOTYDE: FDA Approval
o 	IMAAVY: FDA Submission
o 	Nipocalimab: U.S. FDA Fast Track designation; Phase 2b JASMINE study
o 	Pasritamig: Early study results
o 	RYBREVANT: Phase 1b/2 OrigAMI-1 study
o 	RYBREVANT FASPRO: Phase 1b/2 OrigAMI-4 study; U.S. FDA Breakthrough Therapy Designation;
FDA Approval- EGFR-targeted therapy
o 	TECVAYLI: Phase 3 MajesTEC-9 study
o 	TECVAYLI & DARZALEX FASPRO: FDA Approval; Quadruplet regimen approved in the U.S.;
European Medicines Agency Submission
o 	TREMFYA: QUASAR long-term extension (LTE) study
• 	MedTech:
o 	EP: OMNYPULSE OMNY-AF Pilot Study at 2026 AF Symposium
o 	Surgery: OTTAVA FDA Submission
o 	Vision: FDA Approval of TECNIS PureSee Intraocular Lens

-- 3 of 6 --

J&J earnings calls:
• 	Q4 2025 earnings call: Full year 2026 Operational Sales Guidance of $99.5B - $100.5B or 5.7% - 6.7% and
Adjusted Operational Earnings Per Share of $11.28 - $11.48 or 4.5% - 6.5% was provided on our
Q4 2025 Earnings Call. For your convenience, the final Q4 2025 earnings transcript and presentation are
attached. Full Q4 2025 earnings call operational commentary and key drivers can be listened to here and the
Q4 2025 10-K can be found here.
• 	Q1 2025 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth
rates for Q1 2025. Full Q1 2025 operational commentary, key drivers, and one-timers can be listened
to here and the Q1 2025 10-Q can be found here. For your convenience, the final Q1 2025 earnings transcript
and presentation are attached.
Q1 2025:
o 	Enterprise: $21.9B, 4.2% operational sales growth and 3.3% adjusted operational sales growth
 	Enterprise sales highlights can be found on page 6 of the final Q1 2025 earnings transcript attached
 	P&L highlights can be found on page 7 of the final Q1 2025 earnings transcript attached
o 	Innovative Medicine: $13.9B, 4.2% operational sales growth
 	Innovative Medicine sales highlights can be found on page 6 of the final Q1 2025 earnings transcript
attached
o 	MedTech: $8.0B, 4.1% operational sales growth
 	MedTech sales highlights can be found on page 6-7 of the final Q1 2025 earnings transcript
attached

-- 4 of 6 --

1 	Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2025
(Unaudited; Dollar in millions)
Earnings before provision for taxes on income by segment
1
Innovative Medicine
Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$1 3,873 	1 00.0 	$1 5,202 	1 00.0 	$1 5,563 	1 00.0 	$1 5,763 	1 00.0 	$60,401 	1 00.0
Cost of products sold (COGS) 	4,020 	29.0 	3,978 	26.2 	3,672 	23.6 	3,976 	25.2 	1 5,646 	25.9
Selling, marketing and administrative expenses (SM&A) 	2,261 	1 6.3 	2,789 	1 8.3 	2,869 	1 8.5 	3,456 	21 .9 	1 1 ,375 	1 8.8
Research and development expense (R&D)* 	2,548 	1 8.4 	2,869 	1 8.9 	2,944 	1 8.9 	3,466 	22.0 	1 1 ,827 	1 9.6
Other segment items 	1 	(1 66) 	(1 .2) 	1 4 	0.1 	(368) 	(2.4) 	(1 93) 	(1 .2) 	(71 3) 	(1 .2)
Adjusted segment income before tax 	2 	$5,21 0 	37.5 	$5,552 	36.5 	$6,446 	41 .4 	$5,058 	32.1 	$22,266 	36.9
Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$1 3,873 	1 00.0 	$1 5,202 	1 00.0 	$1 5,563 	1 00.0 	$1 5,763 	1 00.0 	$60,401 	1 00.0
Cost of products sold (COGS) 	3,371 	24.3 	3,1 80 	20.9 	3,093 	1 9.9 	3,261 	20.7 	1 2,905 	21 .4
Selling, marketing and administrative expenses (SM&A) 	2,261 	1 6.3 	2,789 	1 8.3 	2,869 	1 8.4 	3,456 	21 .9 	1 1 ,375 	1 8.8
Research and development expense (R&D)* 	2,548 	1 8.4 	2,869 	1 8.9 	2,944 	1 8.9 	3,466 	22.0 	1 1 ,827 	1 9.6
Other segment items 	1 	(204) 	(1 .5) 	(1 29) 	(0.8) 	(238) 	(1 .5) 	(1 35) 	(0.9) 	(706) 	(1 .2)
Adjusted segment income before tax 	2 	$5,897 	42.5 	$6,493 	42.7 	$6,895 	44.3 	$5,71 5 	36.3 	$25,000 	41 .4
As reported
Q1 	Q2 	Q3 	Q4 	YTD
Adjusted
Q1 	Q2 	Q3 	Q4 	YTD

-- 5 of 6 --

1 	Other segment items for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
2025
(Unaudited; Dollar in millions)
Earnings before provision for taxes on income by segment
2
MedTech
Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	1 00.0 	$8,541 	1 00.0 	$8,430 	1 00.0 	$8,801 	1 00.0 	$33,792 	1 00.0
Cost of products sold (COGS) 	3,326 	41 .5 	3,638 	42.6 	3,61 2 	42.9 	3,973 	45.1 	1 4,549 	43.1
Selling, marketing and administrative expenses (SM&A) 	2,656 	33.1 	2,862 	33.5 	2,801 	33.2 	3,035 	34.5 	1 1 ,354 	33.6
Research and development expense (R&D)* 	677 	8.4 	647 	7.6 	728 	8.6 	786 	8.9 	2,838 	8.4
Other segment items 	1 	(60) 	(0.7) 	1 90 	2.2 	2 	- 	806 	9.2 	938 	2.8
Adjusted segment income before tax 	2 	$1 ,421 	1 7.7 	$1 ,204 	1 4.1 	$1 ,287 	1 5.3 	$201 	2.3 	$4,1 1 3 	1 2.1
Amount 	% to Sale s 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,020 	1 00.0 	$8,541 	1 00.0 	$8,430 	1 00.0 	$8,801 	1 00.0 	$33,792 	1 00.0
Cost of products sold (COGS) 	2,795 	34.8 	3,1 42 	36.8 	3,1 1 9 	37.0 	3,435 	39.0 	1 2,491 	37.0
Selling, marketing and administrative expenses (SM&A) 	2,656 	33.1 	2,862 	33.5 	2,801 	33.2 	3,035 	34.5 	1 1 ,354 	33.6
Research and development expense (R&D)* 	671 	8.4 	690 	8.1 	728 	8.6 	786 	8.9 	2,875 	8.5
Other segment items 	1 	(1 82) 	(2.2) 	(53) 	(0.6) 	1 5 	0.2 	1 0 	0.2 	(21 0) 	(0.6)
Adjusted segment income before tax 	2 	$2,080 	25.9 	$1 ,900 	22.2 	$1 ,767 	21 .0 	$1 ,535 	1 7.4 	$7,282 	21 .5
As reported
Q1 	YTD
Adjusted
Q1 	YTD
Q2
Q2
Q3
Q3
Q4
Q4

-- 6 of 6 --